Clinical trials: Chronic Nephropathy
Chronic Kidney Disease, Albuminuria
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
Vascular endothelial dysfunction increases cardiovascular (CV) risk and contributes to the progression of chronic kidney disease (CKD).
- Trial name
- VEMAKD (NCT02497300)
- Testing
- Spironolactone, Amiloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Alabama at Birmingham
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01651000
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- OPKO IP Holdings II, Inc.
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
- Trial name
- NCT02648347
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 439 sites in United States, Argentina and 18 more
- Volunteers
- 1,751 people
- Sponsor
- Akebia Therapeutics
Renal Failure Chronic Requiring Hemodialysis
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
The purpose of this study is to confirm the safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD)…
- Trial name
- NCT01322347
- Testing
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Where
- 40 sites in United States, Canada
- Volunteers
- 294 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Kidney Failure, Chronic
Clinical Study to Assess the Performance of the Dialyzer With Endexo™
Endexo™ is an additive that is blended into the fiber solution during manufacturing of the hemodialyzer hollow fibers. The intended purpose of the additive is to increase blood compatibility in the finished dialyzer, which is…
- Trial name
- NCT03536663
- Testing
- Optiflux and Dialyzer with Endexo
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Diseases, Alport Syndrome
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with…
- Conditions
- Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
- Trial name
- EAGLE (NCT03749447)
- Testing
- Bardoxolone methyl
- Where
- 87 sites in United States, Australia and 4 more
- Volunteers
- 270 people
- Sponsor
- Biogen
Chronic Kidney Disease, Chronic Hepatitis C
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
- Trial name
- NCT02946034
- Testing
- Viekira Pak ± ribavirin, Mavyret
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Safety Issues, Chronic Kidney Disease
Care Coordination/Home Telehealth to Safeguard Care in CKD
Home telehealth monitoring of veterans with chronic kidney disease, with a disease management protocol and safety-specific decision support, will increase the detection of adverse safety events, and in turn, reduce the need for…
- Trial name
- CCHT in CKD (NCT03038126)
- Testing
- CCHT, Usual care
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Maryland, Baltimore
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents…
- Trial name
- NCT00224042
- Testing
- Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Watson Pharmaceuticals
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Trial name
- NCT05543928
- Testing
- CTAP101
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Diseases
everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
Prospective, single-center study to evaluate the everlinQ endoAVF System when used to create an endoAVF in hemodialysis patients.
- Trial name
- NCT03708562
- Testing
- everlinQ endoAVF System
- Where
- Paraguay
- Volunteers
- 24 people
- Sponsor
- C. R. Bard
End-stage Renal Disease, Chronic Kidney Diseases
Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
The study is a- 2-arm randomized controlled trial among patients presenting for kidney transplant evaluation at a single transplant center to compare the effects of a patient-based self-learning and outreach intervention about…
- Trial name
- KidneyTIME (NCT05154773)
- Testing
- Kidney donation and transplant information made easy
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- State University of New York at Buffalo
Kidney Disease
Uric Acid and the Endothelium in CKD
This study will test the hypothesis that uric acid impairs the function of vessels in patients with kidney disease
- Trial name
- NCT01228903
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Colorado, Denver
Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease
Study evaluating the efficacy and safety of intravenous (IV) ferumoxytol compared with oral iron for the treatment of pediatric participants with chronic kidney disease (CKD).
- Trial name
- NCT01155388
- Testing
- Ferumoxytol, Oral Iron
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
ESRD
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
By 2030 an estimated 2 million people in the US will need dialysis or transplantation for advanced kidney failure. An even more disturbing statistic is that mortality in End Stage Renal Disease (ESRD) is six times higher than in…
- Trial name
- INSPIRED (NCT02278562)
- Testing
- anakinra, actos
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease, Left Ventricular Hypertrophy
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
- Trial name
- PRIMO (NCT00497146)
- Testing
- paricalcitol
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 227 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Diseases, Hypertension
Chronic Kidney Disease Clinical Decision Support
To prevent serious chronic kidney disease (CKD) complications such as end-stage renal disease and cardiovascular events, better strategies are needed to identify, treat, and refer CKD patients seen in primary care clinics.
- Conditions
- Chronic Kidney Diseases, Hypertension, Diabetes
- Trial name
- CKD-CDS (NCT03890588)
- Testing
- CKD enhanced clinical decision support
- Where
- United States
- Volunteers
- 6,295 people
- Sponsor
- HealthPartners Institute
Anaemia
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable rhEPO to GSK1278863 in approximately 68…
- Trial name
- NCT01587924
- Testing
- GSK1278863, rhEPO
- Where
- 62 sites in United States, Canada and 4 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline